secwatch.observer — SEC 8-K summary
======================================

Issuer:     KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
CIK:        0001877184
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001193125-26-110720
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kestra Medical Q3 FY26 revenue $24.6M (+63% YoY); FY26 guidance raised to $93M
------------------------------------------------------------------------------

- Revenue of $24.6M, up 63% YoY; gross margin expanded to 52.6% from 43.4%.
- Prescriptions written for ASSURE system up 58% to 5,462; driven by market share gains.
- GAAP net loss widened to $34.2M vs $21.8M; adjusted EBITDA loss $21.2M vs $16.3M.
- FY26 revenue guidance increased to $93M, representing 55% growth over FY25.
- Cash and equivalents $291M after December 2025 equity offering of 6.9M shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1877184/000119312526110720/0001193125-26-110720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1877184/000119312526110720/ck0001877184-20260317.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-110720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer